Alibaba Health Information Technology Ltd Stock Forecast
Alert
Its only available to paid users.
HKD 7.71
(+35.74%)
Based on the Alibaba Health Information Technology Ltd stock forecasts from 0 analysts, the average analyst target price for Alibaba Health Information Technology Ltd is HKD 7.71 over the next 12 months. Alibaba Health Information Technology Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Alibaba Health Information Technology Ltd is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Alibaba Health Information Technology Ltd’s stock price was HKD 5.68. Alibaba Health Information Technology Ltd’s stock price has changed by -10.97% over the past week, -6.43% over the past month and +11.81% over the last year.
No recent analyst target price found for Alibaba Health Information Technology Ltd
No recent average analyst rating found for Alibaba Health Information Technology Ltd
Company Overview
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. It offers range of prescription drugs, over-the-counter drugs, nutritional supplements, medical devices, contact lenses, and various other health-related products through its online stores on Tmall.com and offline pharmacy outlets to business-to-customer and business-to-business customers; and pharmaceutical products, medical devices and healthcare products, health food, sexual health and family planning products, contact lenses, and medical and healthcare services through its e-commerce platform. The company also provides medical and healthcare services, including medical checkups, nucleic acid testing, medical consultation, registration, vaccination, and TCM through various channels, such as Taobao, Tmall, Alipay, Dr. Deer APP, Gaode, DingTalk, and Quark. In addition, it engages in the tracking business; provision of network hospital, healthcare related internet information, internet information, and healthcare related technical services; operation of internet hospitals; and asset management services. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited is based in Causeway Bay, Hong Kong. Address: Tower One, Causeway Bay, Hong Kong Read Less
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. It offers range of prescription drugs, ove...Read More
Stock Target Advisor's fundamental analysis for Alibaba Health Information Technology Ltd's stock is Slightly Bearish.
Unfortunately we do not have enough data on 0241:HK's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 0241:HK's stock to indicate what its average analyst target is.
0241:HK stock's Price/Earning ratio is 581.00.
Our analysis grades 0241:HK stock's Price / Earning ratio at F. This means that 0241:HK stock's Price/Earning ratio is above 86% of the stocks in the Pharmaceutical Retailers sector in the HK exchange.
Based on this 0241:HK may be a overvalued for its sector.
The last closing price of 0241:HK's stock was HKD 5.68.
The most recent market capitalization for 0241:HK is HKD 82.61B.
Unfortunately we do not have enough analyst data on 0241:HK's stock to indicate whether its price will go up or not.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 0241:HK !
Please login to proceed
Sorry - extended search is only available for registered users.
